# A Study to Evaluate the Effects of ASP5502 in Healthy Adults and Adults With Primary Sjögren's Syndrome

> **NCT06544642** · PHASE1 · TERMINATED · sponsor: **Astellas Pharma Global Development, Inc.** · enrollment: 116 (actual)

## Conditions studied

- Healthy Volunteers
- Sjögren's Syndrome

## Interventions

- **DRUG:** ASP5502
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06544642
- **Lead sponsor:** Astellas Pharma Global Development, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2024-08-21
- **Primary completion:** 2026-03-05
- **Final completion:** 2026-03-05
- **Target enrollment:** 116 (ACTUAL)
- **Why stopped:** Company's strategic decision
- **Last updated:** 2026-03-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06544642

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06544642, "A Study to Evaluate the Effects of ASP5502 in Healthy Adults and Adults With Primary Sjögren's Syndrome". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06544642. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*